Canaccord Genuity Reiterates a 'Buy' on Amarin Corporation (AMRN); CMC: Last Piece of Puzzle in AMR101 NDA
Tweet Send to a Friend
Get Alerts AMRN Hot Sheet
Price: $6.98 -0.99%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade AMRN Now!
Canaccord Genuity reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $25.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on AMR101commercial, partnering potential. We think AMR101, Amarin’s 96% EPA omega-3, will be approved for hypertriglyceridemia in H2/12, likely around its July 26 PDUFA date, with a broad label that will include ANCHOR trial mixed dyslipidemia data. We expect additional IP and business development progress in H2/12."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $11.66 yesterday, with a 52 week range of $5.99-$16.76.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ritu Baral, said, "Reiterate rating and price target on AMR101commercial, partnering potential. We think AMR101, Amarin’s 96% EPA omega-3, will be approved for hypertriglyceridemia in H2/12, likely around its July 26 PDUFA date, with a broad label that will include ANCHOR trial mixed dyslipidemia data. We expect additional IP and business development progress in H2/12."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $11.66 yesterday, with a 52 week range of $5.99-$16.76.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- First Time Cruisers Pass on Carnival (CCL); Wells Fargo Cuts to Market Perform
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
Create E-mail Alert Related Categories
Analyst Comments, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
